Early White Discoloration of Infantile Hemangioma

A Sign of Impending Ulceration

Sheilagh M. Maguiness, MD; William Y. Hoffman, MD; Tim H. McCalmont, MD; Ilona J. Frieden, MD

**Objective:** To evaluate the relationship between early white discoloration of infantile hemangioma (IH) and ulceration.

**Design:** Retrospective cohort study.

**Setting:** Tertiary referral center.

**Patients:** A case series of 11 infants with early white discoloration of IH are described. An additional 55 infants with IH, aged 3 months, were evaluated retrospectively from a photograph archive to further explore the relationship between early white discoloration and presence or development of ulceration.

**Main Outcome Measures:** Patient demographics and hemangioma size, location, and subtype are documented. Sensitivity and specificity of white discoloration in relationship to ulceration are estimated.

**Results:** Ten of the 11 infants in the case series were girls (90%); all IHs were of segmental or indeterminate subtype. Average age at first ulceration was 2.6 months, with average age at healing 5.2 months. No intervention halted progression of ulceration. Of the 55 additional 3-month-old infants, 14 had white discoloration and 12 of these 14 had or developed ulceration (86%). When the hemangioma was either white or slightly white, sensitivity for predicting ulceration was 1.00 (95% confidence interval [CI], 0.78-1.00), with a specificity of 0.68 (95% CI, 0.51-0.81). In contrast, in infants with either slightly white or no white discoloration, the sensitivity for not developing ulceration was 0.80 (95% CI, 0.52-0.96), with a specificity of 0.95 (95% CI, 0.83-0.99), suggesting that a lack of substantial white discoloration early in infancy indicates low risk of ulceration.

**Conclusion:** Early white discoloration of infantile hemangioma is highly suggestive of impending ulceration.

Arch Dermatol. 2010;146(11):1235-1239

---

**Infantile Hemangiomas** (IHs) are the most common benign vascular tumors of infancy. Ulceration is the most common IH complication, occurring in approximately 15.8% of cases in a referral population. Most hemangiomas have a predictable and characteristic growth pattern. They are either absent or present as precursor lesions at birth and go on to proliferate rapidly over the first few months of life, with proliferation typically completed by age 4 to 6 months.

During the proliferative phase of hemangioma growth, the clinical appearance is usually a brightly erythematous plaque with slight follicular accentuation resembling a strawberry, or if the hemangioma is mixed (ie, has both superficial and deep components), it may appear as a bluish soft-tissue nodule with a brightly erythematous plaque at the surface. These clinical appearances usually predominate throughout the first 4 months of life.

The clinical characteristics heralding involution include simultaneous softening of the tumor and a milky white or gray discoloration of the superficial surface typically beginning in the center and progressing centrifugally. Involution can begin when the child is as young as a few months, but more commonly it begins after IH growth has been completed, between ages 5 and 10 months.

We describe herein 11 infants in whom early white discoloration of the IH surface (Figure 1) heralded extensive, relentless ulceration, a finding we refer to as the “early white hemangioma” sign (Figure 2 and Figure 3). To confirm the significance of this finding, we evaluated 55 more infants selected from a photograph archive of patients with IH to determine the degree to which early whitening of IH predicted ulceration.
In the retrospective cohort of 11 patients with early white discoloration of IH, we recorded information regarding clinical characteristics, location, size, morphologic traits, and treatment methods (Table). As a second component of the study, to determine the specificity of early whitening, we analyzed a consecutive, cross-sectional sample of clinical photographs of 55 three-month-old infants with IH. Patients were excluded from evaluation in this cross-sectional study if they did not have follow-up visits for at least 2 more months. The patients’ sex and history of ulceration were recorded as were the location, distribution, and extent of white IH discoloration. We recorded whether the IHs were white, slightly white, or not white at 3 months, as judged by unblinded investigators (S.M.M. and I.J.F.). If a substantial amount of the hemangioma exhibited white discoloration, it was considered white. Slightly white hemangiomas were those with less than 20% white discoloration. Both studies were approved by the University of California, San Francisco committee on human research.

Patient 1 was born at 36 weeks’ gestation of an uncomplicated pregnancy. She was seen at our pediatric dermatology clinic at age 3.5 months with a giant (>500 cm²), mixed, segmental hemangioma covering her entire mid thoracic spine (Figure 1). On initial examination, we found a reticulate white and gray...
appearance to the entire tumor and maceration within skin folds. Suspecting a high risk of ulceration, we treated the patient with low-dose oral corticosteroids (prednisolone, 1 mg/kg/d divided twice daily) and low-dose aspirin.

At age 4 months, on return to clinic, the infant had multiple sites of ulceration, and treatment at this time included conservative local wound care with metronidazole gel, petrolatum (Aquaphor; Beiersdorf Inc, Hamburg, Germany), topical platelet-derived growth factor (PDGF) (becaplermin gel), and nonadherent dressings. At age 5 months, the patient was seen again for dramatic, extensive ulceration of the entire tumor with substantial pain (Figure 4). Bacterial infection with methicillin-sensitive *Staphylococcus aureus* was also present. Owing to the extensive ulceration and pain, the patient underwent surgical debridement and primary closure of the largest involved areas. All systemic therapy was discontinued.

Histopathologic findings of the lesion included substantial necrosis of the hemangioma down to fascia. Scattered areas of fibrosis were found in the superficial dermis, which appeared to correspond to clinically whitened areas (Figure 5). Magnetic resonance imaging of the spine and brain showed extensive soft-tissue hemangioma of the thoracic spine as well as intraspinal involvement and involvement of the aorta. Ongoing ulceration, chronic pain, and frequent staphylococcal superinfection necessitated treatment with interferon alfa-2b at age 14 months.

### RESULTS

The Table summarizes the clinical characteristics, treatments, and time to healing in all 11 patients. The average age at the time of ulceration in our cohort was 2.6 months, and the average age at healing was 5.2 months. All patients received some form of wound care, principally petrolatum, metronidazole gel, and nonadherent dressings. Most (9 of 11) received topical PDGF (becaplermin gel). Oral corticosteroids were given in 6 of 11 cases, low-dose-aspirin in 3 cases, and oral propranolol in 1 case. None of these treatments seemed effective at halting the progression of ulceration; however, topical becaplermin appeared to accelerate wound-healing in 2 patients. Pulsed-dye laser treatment resulted in fast and complete healing in 2 patients, and early surgical excision in 2 patients also helped to control pain, and the surgical wounds healed promptly.

<table>
<thead>
<tr>
<th>Patient No./ Sex/Gestational Age, wk</th>
<th>Hemangioma Location</th>
<th>Size, cm²</th>
<th>Subtype</th>
<th>Age at First Ulceration, mo</th>
<th>Treatment</th>
<th>Age at Healing, mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/F/36 Back</td>
<td>500</td>
<td>Segmental</td>
<td>4</td>
<td>Becaplermin, prednisolone, aspirin, surgical resection</td>
<td>&gt;14</td>
<td></td>
</tr>
<tr>
<td>2/F/37 Shoulder</td>
<td>35</td>
<td>Segmental</td>
<td>2</td>
<td>Becaplermin, aspirin</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>3/F/36 Face</td>
<td>110</td>
<td>Segmental</td>
<td>0.5</td>
<td>Becaplermin, prednisolone ×3 mo</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>4/F/40 Perineal</td>
<td>100</td>
<td>Segmental</td>
<td>0.75</td>
<td>Becaplermin, prednisolone, interferon¹</td>
<td>Still not healed at 5 ¹</td>
<td></td>
</tr>
<tr>
<td>5/M/40 Shoulder</td>
<td>32.5</td>
<td>Indeterminate</td>
<td>2</td>
<td>Prednisolone ×2 wk, PDL</td>
<td>3.5</td>
<td></td>
</tr>
<tr>
<td>6/F/38 Torso</td>
<td>14</td>
<td>Indeterminate</td>
<td>6</td>
<td>Becaplermin, PDL</td>
<td>6.75b</td>
<td></td>
</tr>
<tr>
<td>7/F/39 Thigh</td>
<td>42</td>
<td>Indeterminate</td>
<td>2.5</td>
<td>Becaplermin, prednisolone, aspirin ×2 wk</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>8/F/32 Face</td>
<td>10.5</td>
<td>Indeterminate</td>
<td>2.5</td>
<td>Becaplermin, PDL</td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>9/F/40 Trunk</td>
<td>43</td>
<td>Segmental</td>
<td>3.5</td>
<td>Surgical excision</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>10/F/37 Perineal</td>
<td>60</td>
<td>Segmental</td>
<td>3</td>
<td>Becaplermin</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>11/F/33 Forearm</td>
<td>75</td>
<td>Segmental</td>
<td>2</td>
<td>Becaplermin, PDL, propranolol</td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: PDL, pulsed-dye laser.

¹One patient with an extensive perineal hemangioma causing urinary obstruction received interferon at another institution and was not seen in follow-up at our institution.

²Pulsed-dye laser in this patient accelerated healing within 3 weeks.
Ulceration is the most common complication of IH. The incidence in a referral population is generally reported to be between 15% and 25%. In a prospective study of 1096 patients reported by Chamlin et al, the median age at ulceration was 4.0 months, which correlates with the end of the proliferative phase of hemangioma growth (patient age 4-6 months). In our study, patients had even earlier ulceration (age 2.6 months) than is typically seen. Early gray-white discoloration in the columellar area, a sign of impending cartilage destruction, has been reported in 3 infants with segmental facial hemangiomas involving the upper lip and perinasal skin, a finding strikingly similar to our patients with early white-gray discoloration. As in our patients, no treatment was effective in halting progressive ulceration.

The histopathologic analysis in 2 of our patients showed fibrosis in the upper dermis. A similar exuberant fibrocytic reaction was recently reported in small, localized, early-regressing IH. These findings may imply a different mechanism of action leading to early regression or ulceration. In both specimens, negative p53 staining suggests that accelerated apoptosis cannot explain the early ulceration. Recently, the role of hypoxia in hemangioma proliferation has been studied. Hypoxia-inducible factor (HIF) and related cytokines are elevated in proliferating hemangiomas, indicating a possible role for hypoxia in the development of IHs. It is possible that the fibrosis seen in patients with early white discoloration of IHs may form as a result of tissue hypoxia, as in certain types of scarring processes such as keloids in which HIF is also upregulated. A study examining ultrasonograms of cutaneous hemangiomas did not show correlation between blood vessel flow characteristics and likelihood of ulceration. This raises the possibility that hypoxia may be related to tissue oxygenation, occurring within smaller vessels, and lead-
ing to fibrosis and then to ulceration. Although not definitively proven, the white color change perceived at the surface of this interesting group of hemangiomas may correspond to the scarlike areas of superficial dermal fibrosis.

In conclusion, early white discoloration of IH appears to be highly sensitive and relatively specific for predicting hemangioma ulceration. This finding in infants younger than 3 months, rather than heralding early involution, appears to be a sign of early ulceration. Clinicians should be aware of this phenomenon and anticipate complications in these patients. Anecdotally, early excision (when feasible) and administration of topical becaplermin, pulsed-dye laser, and oral propranolol were useful in expediting healing and controlling pain.

Accepted for Publication: April 8, 2010.

Correspondence: Sheilagh M. Maguiness, MD, Department of Pediatric Dermatology, Children’s Hospital Boston, 300 Longwood Ave, Fegan 6, Boston, MA 02115 (Sheilagh.Maguiness@childrens.harvard.edu).

Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Maguiness and Frieden. Acquisition of data: Maguiness, Hoffman, and Frieden. Analysis and interpretation of data: Maguiness, McCalmont, and Frieden. Drafting of the manuscript: Maguiness. Critical revision of the manuscript for important intellectual content: Maguiness, Hoffman, McCalmont, and Frieden. Administrative, technical, and material support: Maguiness and Frieden. Study supervision: Maguiness, Hoffman, and McCalmont.

Financial Disclosure: Dr McCalmont has served as a consultant for Cutera Lasers and as a medicolegal consultant for dermatopathology cases. Dr Frieden has served as consultant for Pierre Fabre Dermatology.

Additional Contributions: Alan Bostrom, MD, assisted with the statistical analysis in this study.

Announcement

Edward W. Cowen, MD, MHSc, joins the editorial board of the Archives of Dermatology as the section editor of The Cutting Edge: Challenges in Medical and Surgical Therapies. Dr Cowen currently serves as the chief of the National Institutes of Health Consultation Service. In 2009, he received the Outstanding Clinical Science Award of the Fifth Annual National Cancer Institute Center for Cancer Research Retreat. His current primary research interests are the natural history of graft-versus-host disease and the efficacy of imatinib, extracorporeal photopheresis, and montelukast in treating graft-versus-host disease.

We welcome Dr Cowen to the Archives editorial family.

June K. Robinson, MD, Editor
Jeffrey P. Callen, MD, Associate Editor

References